Drug Use Investigation Of Azithromycin Iv
Overview
- Phase
- Not Applicable
- Intervention
- Azithromycin IV
- Conditions
- Pneumonia
- Sponsor
- Pfizer
- Enrollment
- 403
- Primary Endpoint
- Number of Participants With Treatment-Related Adverse Events
- Status
- Completed
- Last Updated
- 9 years ago
Overview
Brief Summary
To collect the efficacy and safety information of Azithromycin IV related to their appropriate use in daily practice
Investigators
Eligibility Criteria
Inclusion Criteria
- •Male or Female patients who are prescribed Zithromac IV for pneumonia or pelvic inflammatory disease.
Exclusion Criteria
- •Subjects who have been prescribed Zithromac IV for pneumonia or pelvic inflammatory disease.
Arms & Interventions
Azithromycin IV
Subjects who are treated with Azithromycin IV
Intervention: Azithromycin IV
Outcomes
Primary Outcomes
Number of Participants With Treatment-Related Adverse Events
Time Frame: 29 days
A treatment-related adverse event was any untoward medical occurrence attributed to Zithromac Intravenous use (and Zithromac Tablets) in a participant who received Zithromac Intravenous use (and Zithromac Tablets). A treatment-related serious adverse event was a treatment-related adverse event resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; lifethreatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Relatedness to Zithromac Intravenous use (and Zithromac Tablets) was assessed by the physician.
Secondary Outcomes
- Clinical Effectiveness Rate in Participants With Pelvic Inflammatory Disease(29 days)
- Clinical Effectiveness Rate in Participants With Pneumonia(29 days)